| From: Frank Sully | 5/6/2021 1:13:36 PM | | | | | | Global Ai In Pharma Market Report 2021: Long-term Forecast to 2025 & 2030 Featuring Novartis, IBM Watson, Microsoft, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Exscientia, and Cyclica
Thu, May 6, 2021, 7:30 AM·5 min read
This report focuses on Ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in pharma market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Major players in the artificial intelligence (AI) in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Inc., Exscientia, and Cyclica.
The global AI in pharma market is expected to grow from $0.91 billion in 2020 to $1.27 billion in 2021 at a compound annual growth rate (CAGR) of 39%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.94 billion in 2025 at a CAGR of 47%.
The artificial intelligence (AI) in pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, deep learning; by drug type into small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction.
North America was the largest region in the AI in pharma market in 2020. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period.
The shortage of AI skills is seen as a major barrier to the pace of technology's adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market.
In November 2018, Cyclica, a Canadian biotechnology company that leverages AI and computational biophysics to decentralize drug discovery collaborated with Bayer on drug discovery programs. These companies will increase drug discovery applications by increasing intelligence into the polypharmacological outlines of small molecules while further developing Cyclica's integrated system of licensing technologies. Bayer, a German multinational pharmaceutical company, includes human and veterinary pharmaceuticals, agricultural chemicals, seeds, and biotechnology products.
The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10-15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs.
For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market.
Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Companies Mentioned
Novartis
IBM Watson
Microsoft Corporation
Merck
GNS Healthcare
Google
AstraZeneca
Atomwise Inc.
Exscientia
Cyclica
NVIDIA Corporation
XtalPi Inc.
BenevolentAI
Cloud Pharmaceuticals Inc
BERG LLC
Bayer
Pfizer
Recursion Pharmaceuticals Inc.
Bristol-Myers Squibb |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: chowder | 5/6/2021 1:29:14 PM | | | | | | If anyone has an interest in SQ, they announce earnings after the market close today. If their report is anything like PYPL's was, it's possible SQ will show a nice pop in price. This is one example of where I will sometimes front run an earnings report as opposed to waiting post announcement.
SQ is down 3.57% as I type. I could be wrong but I'm thinking it will take a terrible report to cause price to dip much further. An earnings surprise to the upside though might cause price to have a nice pop tomorrow.
Again, this just an opinion but it is an example of how I play earnings announcements. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: chowder | 5/6/2021 4:23:52 PM | | | | | | Square EPS beats by $0.25, beats on revenue
May 06, 2021 4:13 PM ET Square, Inc. (SQ) By: Gaurav Batavia, SA News Editor 8 Comments
Square (NYSE: SQ): Q1 Non-GAAP EPS of $0.41 beats by $0.25; GAAP EPS of $0.08 beats by $0.14.
Revenue of $5.06B (+266.7% Y/Y) beats by $1.73B.In the first quarter of 2021, mid-market Seller GPV increased 43% year over year, more than 2x the growth of total Seller GPV.
Okay, now we'll see what sort of follow through we have. It was down 3.5% at the time of my comment, went down to 7% later in the session. Let's see where it opens tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: chowder who wrote (290) | 5/6/2021 5:12:21 PM | | From: inspbudget | | | | The general mood of growth stocks and the NASDAQ overall has been ugly the past couple weeks.
I hope that the Stock Price will improve, but looking at after hours action, would not be altogether surprised if it drops tomorrow. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Frank Sully | 5/6/2021 11:18:35 PM | | | | | | Global CRISPR and CAS Gene Market to Surpass US$ 3,494.4 Million by 2027, Says Coherent Market Insights (CMI)
Wed, May 5, 2021, 10:00 AM
According to Coherent Market Insights, the global CRISPR and CAS gene market is estimated to be valued at US$ 830.7 million in 2020 and is expected to exhibit a CAGR of 22.8% during the forecast period (2020-2027).
Key Trends and Analysis of the Global CRISPR and CAS Gene Market:
Key trends in the market include increasing research and development activities, product launches, inorganic activities such as collaborations, and others.
Key players are focusing on increasing research and development for new treatments for genetic disorders, which is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, in June 2019, GlaxoSmithKline Plc partnered with gene-editing pioneers based at the University of California (UC) to establish a new laboratory that aims to speed up discovery of new treatments by exploring how gene mutations cause disease, and developing new CRISPR-based technologies.
Market players are indulged in launching new kits, which is expected to drive growth of the market over the forecast period. For instance, in June 2019, Synthego, a global genome engineering solutions company, announced the launch of the Gene Knockout Kit v2. This is the only product that leverages a novel bioinformatics- powered multi-guide strategy to guarantee a gene knockout. The kit will accelerate research by saving scientists from multiple trial-and-error cycles in optimizing their CRISPR experiment.
Various biotechnology and pharmaceutical companies are focusing on collaborations to conduct research and development for treatment of diseases such as cancer, AIDS, genetic diseases, and others, which is expected to drive growth of the market. For instance, in October 2019, CRISPR Therapeutics and Bayer announced plans for a joint venture between CRISPR Therapeutics and Bayer and Casebia Therapeutics would operate under the direct management of CRISPR Therapeutics. Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology, and autoimmune diseases.
Key Market Takeaways:
Increasing prevalence of genetic disorders such as Down’s syndrome, Sickle cell anemia, and Huntington’s disease worldwide is expected to drive the growth of the global CRISPR and CAS gene market over the forecast period. For instance, according to National Health Service (NHS) U.K., 2018 report, the highest rate of Huntington’s disease in the U.K. is 12 per 100,000 people.
Among all the regions, North America is expected to hold a dominant position in the global CRISPR and CAS gene market over the forecast period, owing to the increasing number of research studies regarding the CRISPR and CAS gene technology in the region. For instance, in 2017, Editas partnered with Juno Therapeutics for cancer-related research using CRISPR. Under the terms of the agreement, Juno had to pay Editas an initial payment of US$ 25 million, in which up to US$ 22 million will be used in research support for three programs over five years.
Competitive Landscape:
Key players operating in the global CRISPR and CAS gene market include Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), OriGene Technologies, Inc., New England Biolabs, Cellecta, Inc., Agilent Technologies, Inc., Applied StemCell, Inc., Synthego, Genscript, Mirus Bio LLC, Integrated DNA Technologies, Inc., and Mammoth Biosciences, Inc. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: 2hugo who wrote (294) | 5/7/2021 4:14:58 AM | | From: chowder | | | | >> Have you been adding/reducing to disruptive stocks besides crypto in any of your portfolios young/old folk?
Crypto only. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
